MedTrace Logo

The STem Cell Application Researches and Trials In NeuroloGy-2 (STARTING-2) Study

NCT01716481 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-04-26

No results posted yet for this study

Summary

The objectives of this study was to test hypothesis that ischemic stroke patients having moderate to severe persistent neurologic deficit will have better outcomes with intravenous transplantation of autologous mesenchymal stem cells (MSCs) expanded with autologous serum that is obtained at acute phase of stroke than patients receiving standard treatment.

Conditions

  • Stroke, Ischemic

Interventions

OTHER

Mesenchymal stem cell

intravenous transplantation of autologous mesenchymal stem cells expanded with autologous serum

Sponsors & Collaborators

  • Pharmicell Co., Ltd.

    collaborator INDUSTRY

  • Samsung Medical Center

    lead OTHER

Principal Investigators

  • Oh Young Bang, MD · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01716481 on ClinicalTrials.gov